Md. Code, Health - General § 21-2C-05
This is the official text of Md. Code, Health - General § 21-2C-05, part of Maryland’s Code, Health - General — covers public health regulation.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
§21–2C–05.
Official statutory text
(a) (1) A conflict of interest shall be disclosed:
(i) By the Board when hiring Board staff;
(ii) By the appointing authority when appointing members and alternate members to the Board and members to the Stakeholder Council; and
(iii) By the Board, when a member of the Board is recused in any final decision resulting from a review of a prescription drug product.
(2) A conflict of interest shall be disclosed:
(i) In advance of the first open meeting after the conflict is identified; or
(ii) Within 5 days after the conflict is identified.
(b) (1) A conflict of interest disclosed under subsection (a) of this section shall be posted on the website of the Board unless the chair of the Board recuses the member from any final decision resulting from a review of a prescription drug product.
(2) A posting under paragraph (1) of this subsection shall include the type, nature, and magnitude of the interests of the member involved.
(i) By the Board when hiring Board staff;
(ii) By the appointing authority when appointing members and alternate members to the Board and members to the Stakeholder Council; and
(iii) By the Board, when a member of the Board is recused in any final decision resulting from a review of a prescription drug product.
(2) A conflict of interest shall be disclosed:
(i) In advance of the first open meeting after the conflict is identified; or
(ii) Within 5 days after the conflict is identified.
(b) (1) A conflict of interest disclosed under subsection (a) of this section shall be posted on the website of the Board unless the chair of the Board recuses the member from any final decision resulting from a review of a prescription drug product.
(2) A posting under paragraph (1) of this subsection shall include the type, nature, and magnitude of the interests of the member involved.
Status: in_force · Read it on the official government site
Need a lawyer in Maryland?
Find a Maryland lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.